Symbols

RGEN

Repligen·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RGEN

Repligen Corporation

A life sciences company focused on bioprocessing technology leadership

Industry

Biological Technology

Established Date

Listing Date

05/06/1986

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,778

Fiscal Year Ends

12-31

Website

www.repligen.com

Security Type

Common stock

Office address

41 Seyon Street , Bldg. 1 , Suite 100 , Waltham , MA 02453

Business

Introduction

Repligen Corporation is a leader in supplying key biopharmaceutical products. The protein A produced by the company provides long-term supply, long-term contracts for important life science research companies, and is also sold directly to end users in the pharmaceutical processing chain. The company provides professional biological research and development products to SecreFlo's latest drug, which has submitted an application to the US Food and Drug Administration and has received priority testing, and the company has submitted a marketing authorization to the European drug regulatory agency. SecreFlo is a company that develops new imaging agents for synthetic human hormone drugs for the diagnosis of pancreatitis and a variety of potential pancreatic diseases. The company conducts two early research projects on rare diseases of the central nervous system, Friedrich's dyskinesia and spinal muscular atrophy have entered the first phase of clinical trials. In addition, the company has obtained an additional license for intellectual property from Bristol-Myers Squibb, the company's patent rights for the real-price sale of the drug abatacept in the United States. The company was established in May 1981.

Earnings Call

Q2/2025

Estimate EPS0.39

Actual EPS0.37

Estimate Revenue175.05M

Actual Revenue182.00M

Repligen's Q2 2025: Navigating Contradictions in Gene Therapy Revenue and Tariff Strategies

Jul 29,2025 05:41·
Earnings Decrypt

Q3/2025

Estimate EPS0.42

Actual EPS0.46

Estimate Revenue181.72M

Actual Revenue189.00M

Repligen's Q3 2025 Earnings Call: Contradictions Emerge on Market Growth, Tariff Impact, New Modalities, and CDMO Recovery

Oct 28,2025 10:29·
Earnings Decrypt

Company Financials

EPS

RGEN has released its 2025 Q3 earnings. EPS was reported at 0.46, versus the expected 0.42, beating expectations. The chart below visualizes how RGEN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RGEN has released its 2025 Q3 earnings report, with revenue of 188.81M, reflecting a YoY change of 21.91%, and net profit of 14.91M, showing a YoY change of 2379.97%. The Sankey diagram below clearly presents RGEN's revenue sources and cost distribution.